Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

173
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
173
Drug Therapy01:28

Drug Therapy

32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
32
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

341
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
341
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

20
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
20
Long-term Depression01:03

Long-term Depression

2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual function despite hyperprolactinemia: a 24-month analysis of paliperidone palmitate versus haloperidol decanoate.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2026
Same author

Immersive Technologies for Cognitive Rehabilitation in Dementia and Mild Cognitive Impairment: Systematic Review.

Journal of medical Internet research·2026
Same author

Neuropsychiatric and behavioural correlates of sundowning in Alzheimer's disease.

International journal of psychiatry in clinical practice·2026
Same author

Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.

Molecular psychiatry·2026
Same author

Polygenic score for schizophrenia worsens the effect of bipolar disorder course on neuronal metabolism and white matter microstructure.

Psychiatry and clinical neurosciences·2026
Same author

Multilingualism and international mental health research-The barriers for non-native speakers of English.

PLOS mental health·2026

Related Experiment Video

Updated: May 20, 2025

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.3K

Anhedonia: Current and future treatments.

Alessandro Serretti1,2

  • 1Department of Medicine and Surgery Kore University of Enna Enna Italy.

PCN Reports : Psychiatry and Clinical Neurosciences
|March 25, 2025
PubMed
Summary

Anhedonia interventions, including medications, neuromodulation, and behavioral therapies, show promise for improving patient outcomes and remission rates. Tailoring treatments to individual reward disruptions is key for optimal results.

Keywords:
anhedoniaantidepressantsmajor depressive disorderpsychopharmacology

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.1K
Sucrose Preference and Novelty-Induced Hypophagia Tests in Rats using an Automated Food Intake Monitoring System
07:33

Sucrose Preference and Novelty-Induced Hypophagia Tests in Rats using an Automated Food Intake Monitoring System

Published on: May 8, 2020

10.3K

Related Experiment Videos

Last Updated: May 20, 2025

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.3K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.1K
Sucrose Preference and Novelty-Induced Hypophagia Tests in Rats using an Automated Food Intake Monitoring System
07:33

Sucrose Preference and Novelty-Induced Hypophagia Tests in Rats using an Automated Food Intake Monitoring System

Published on: May 8, 2020

10.3K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Psychology

Background:

  • Anhedonia is a core symptom across various psychiatric disorders, significantly impairing functioning and hindering recovery.
  • Current treatments often show limited efficacy for anhedonia, necessitating exploration of diverse therapeutic avenues.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging interventions for anhedonia.
  • To synthesize evidence on the effectiveness of pharmacological, neuromodulatory, behavioral, and lifestyle-based approaches.

Main Methods:

  • Narrative review of existing literature on anhedonia treatments.
  • Analysis of studies investigating various therapeutic modalities, including medications, neuromodulation, psychotherapy, and novel agents.

Main Results:

  • Pharmacological agents like vortioxetine, agomelatine, bupropion, ketamine, and brexpiprazole demonstrate anti-anhedonic effects, outperforming traditional SSRIs and SNRIs.
  • Neuromodulation techniques (rTMS, tDCS, tVNS) and psychotherapies (behavioral activation, mindfulness, savoring) show efficacy in improving anhedonia.
  • Emerging treatments such as aticaprant and psilocybin exhibit promising results for anhedonia.

Conclusions:

  • Improving anhedonia is linked to enhanced psychosocial functioning, quality of life, and sustained remission.
  • Routine assessment and tailored interventions addressing specific reward pathway disruptions are crucial for optimizing patient outcomes.